- Trial phase
- Approved
- Time to market
- Already approved and commercially available in the U.S. (since September 2020) and EU (since June 2021).
- Why 3/10
- Onureg is already approved and commercially marketed with no pending regulatory decision (PDUFA, AdComm, or pivotal readout) in the next ~12 months. It is a minor product within BMS's diversified ~$50B revenue portfolio, grouped under "Other Growth Brands" without individually reported revenue. ImpactScore is 3 per the rubric: an approved, marketed drug with no imminent binary catalyst.
Onureg is already approved and marketed with no pending regulatory decision. The next catalysts to watch are data readouts from ongoing early-stage combination trials (CC-486 with venetoclax in AML/MDS), but these are Phase 1/1b and Phase 1/2 studies, not pivotal registrational trials. For a diversified giant like BMS, Onureg is a minor product grouped under "Other Growth Brands" and is unlikely to drive material share-price movement on its own.
Price Chart
Executive Summary
Onureg (oral azacitidine, CC-486) is an already-approved, commercially marketed drug from Bristol Myers Squibb (BMY) for maintenance treatment of adults with acute myeloid leukemia (AML) in first remission. It was FDA-approved on September 1, 2020 based on the Phase 3 QUAZAR AML-001 trial, which showed a nearly 10-month overall survival benefit over placebo. An FDA efficacy supplement (s003) was approved in April 2026 updating the label. Onureg is a small product within BMS's diversified ~$50B annual revenue portfolio, grouped under "Other Growth Brands" without individually reported revenue. The drug faces eventual generic competition as patents begin expiring around 2029-2030, and a Paragraph IV challenge has been filed. Ongoing early-stage trials explore combinations with venetoclax in AML and MDS, but no pivotal readout or regulatory decision is imminent.
How It Works
Onureg is an oral tablet form of azacitidine, a chemotherapy drug that works by interfering with the DNA and RNA of rapidly dividing cancer cells. It is a hypomethylating agent, meaning it helps reactivate genes that can suppress tumor growth. Unlike the injectable version of azacitidine (Vidaza), Onureg can be taken at home as a pill.
Trial Status
Onureg was approved based on the Phase 3 QUAZAR AML-001 trial (NCT01757535), which demonstrated significant overall survival and relapse-free survival benefit versus placebo. The drug is commercially marketed. Ongoing early-stage trials are exploring Onureg in combination with venetoclax for AML (Phase 1/1b, NCT04887857, completed) and higher-risk MDS (Phase 1/2, NCT05782127, recruiting). A hepatic impairment study (NCT05209295) was terminated.
The Two-Sided Case
Upcoming Catalysts
- No upcoming PDUFA, pivotal readout, or regulatory decision identified for Onureg in the next ~12 months.
- Data from the Phase 1/2 trial of Onureg + venetoclax in higher-risk MDS (NCT05782127) could emerge, but this is an early-stage, dose-finding study, not a registrational trial.
- Patent litigation outcomes related to the Paragraph IV challenge could affect generic entry timing.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report